Literature DB >> 26287433

MK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol.

Serena Deiana1, Akihito Watanabe, Yuki Yamasaki, Naoki Amada, Tetsuro Kikuchi, Colin Stott, Gernot Riedel.   

Abstract

Deficiencies in social activities are hallmarks of numerous brain disorders. With respect to schizophrenia, social withdrawal belongs to the category of negative symptoms and is associated with deficits in the cognitive domain. Here, we used the N-methyl-D-aspartate receptor antagonist dizocilpine (MK-801) for induction of social withdrawal in rats and assessed the efficacy of several atypical antipsychotics with different pharmacological profiles as putative treatment. In addition, we reasoned that the marijuana constituent cannabidiol (CBD) may provide benefit or could be proposed as an adjunct treatment in combination with antipsychotics. Hooded Lister rats were tested in the three-chamber version for social interaction, with an initial novelty phase, followed after 3 min by a short-term recognition memory phase. No drug treatment affected sociability. However, distinct effects on social recognition were revealed. MK-801 reduced social recognition memory at all doses (>0.03 mg/kg). Predosing with aripiprazole dose-dependently (2 or 10 mg/kg) prevented the memory decline, but doses of 0.1 mg/kg risperidone or 1 mg/kg olanzapine did not. Intriguingly, CBD impaired social recognition memory (12 and 30 mg/kg) but did not rescue the MK-801-induced deficits. When CBD was combined with protective doses of aripiprazole (CBD-aripiprazole at 12 :  or 5 : 2 mg/kg) the benefit of the antipsychotic was lost. At the same time, activity-related changes in behaviour were excluded as underlying reasons for these pharmacological effects. Collectively, the combined activity of aripiprazole on dopamine D2 and serotonin 5HT1A receptors appears to provide a significant advantage over risperidone and olanzapine with respect to the rescue of cognitive deficits reminiscent of schizophrenia. The differential pharmacological properties of CBD, which are seemingly beneficial in human patients, did not back-translate and rescue the MK-801-induced social memory deficit.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26287433     DOI: 10.1097/FBP.0000000000000178

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  14 in total

1.  Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model.

Authors:  Ashleigh L Osborne; Nadia Solowij; Ilijana Babic; Xu-Feng Huang; Katrina Weston-Green
Journal:  Neuropsychopharmacology       Date:  2017-02-23       Impact factor: 7.853

2.  Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia.

Authors:  Monika Marcinkowska; Adam Bucki; Joanna Sniecikowska; Agnieszka Zagórska; Nikola Fajkis-Zajączkowska; Agata Siwek; Monika Gluch-Lutwin; Paweł Żmudzki; Magdalena Jastrzebska-Wiesek; Anna Partyka; Anna Wesołowska; Michał Abram; Katarzyna Przejczowska-Pomierny; Agnieszka Cios; Elżbieta Wyska; Kamil Mika; Magdalena Kotańska; Paweł Mierzejewski; Marcin Kolaczkowski
Journal:  J Med Chem       Date:  2021-08-26       Impact factor: 7.446

3.  Sociability development in mice with cell-specific deletion of the NMDA receptor NR1 subunit gene.

Authors:  Sarah L Ferri; Ashley A Pallathra; Hyong Kim; Holly C Dow; Praachi Raje; Mary McMullen; Warren B Bilker; Steven J Siegel; Ted Abel; Edward S Brodkin
Journal:  Genes Brain Behav       Date:  2019-12-12       Impact factor: 3.449

4.  Reversible Changes in BDNF Expression in MK-801-Induced Hippocampal Astrocytes Through NMDAR/PI3K/ERK Signaling.

Authors:  Wenjuan Yu; Hongwei Fang; Lei Zhang; Miaowen Hu; Sidi He; Huafang Li; Hao Zhu
Journal:  Front Cell Neurosci       Date:  2021-05-14       Impact factor: 5.505

Review 5.  Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence.

Authors:  Cathrin Rohleder; Juliane K Müller; Bettina Lange; F M Leweke
Journal:  Front Pharmacol       Date:  2016-11-08       Impact factor: 5.810

6.  Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity.

Authors:  Erin W Tuplin; Matthew R Holahan
Journal:  Curr Neuropharmacol       Date:  2017-11-14       Impact factor: 7.363

7.  A non-ionotropic activity of NMDA receptors contributes to glycine-induced neuroprotection in cerebral ischemia-reperfusion injury.

Authors:  Juan Chen; Rong Hu; Huabao Liao; Ya Zhang; Ruixue Lei; Zhifeng Zhang; Yang Zhuang; Yu Wan; Ping Jin; Hua Feng; Qi Wan
Journal:  Sci Rep       Date:  2017-06-15       Impact factor: 4.379

Review 8.  From the Clinic to the Laboratory, and Back Again: Investigations on Cannabinoids and Endocannabinoid System Modulators for Treating Schizophrenia.

Authors:  Kurt Leroy Hoffman
Journal:  Front Psychiatry       Date:  2021-07-05       Impact factor: 4.157

9.  Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life.

Authors:  Ilaria Cuomo; Georgios D Kotzalidis; Simone de Persis; Daria Piacentino; Filippo Perrini; Emanuela Amici; Sergio De Filippis
Journal:  Neuropsychiatr Dis Treat       Date:  2018-06-21       Impact factor: 2.570

10.  Treatment Responses of Cognitive Function and Plasma Asymmetric Dimethylarginine to Atypical Antipsychotic in Patients With Schizophrenia.

Authors:  Zhi-Min Yu; Ying Zhao; Jin-Qiong Zhan; Tao Luo; Jian-Wen Xiong; Bin Yu; Bo Wei; Yuan-Jian Yang
Journal:  Front Psychiatry       Date:  2019-01-10       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.